Results 91 to 100 of about 2,588,337 (304)
Molecular Oncology, EarlyView.Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley +5 more
wiley +1 more source
Suppression of cell cycle progression by Jun dimerization protein (JDP2) involves down-regulation of cyclin A2 [PDF]
, 2009 We report here a novel role for Jun dimerization protein-2 (JDP2) as a regulator of the progression of normal cells through the cell cycle. To determine the role of JDP2 in vivo, we generated Jdp2 knock-out (Jdp2KO) mice by targeting exon 1 to disrupt ...
Atsushi Yoshiki +9 more
core +1 more source
Comparison of the effects of high and low milk-replacer feeding regimens on health and growth of crossbred dairy heifers [PDF]
, 2019 Context: Pre-weaning growth in dairy heifers is highly dependent on the amount of milk fed. Both milk replacer (MR) and associated labour are costly, encouraging restricted milk rations and once-a-day feeding.
Johnson, Kate F. +2 more
core +3 more sources
Molecular Oncology, EarlyView.This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns +10 more
wiley +1 more source
Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers
Molecular Oncology, EarlyView.This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel +6 more
wiley +1 more source
پزشکی بالینی ابن سینا, 1999 A total 97 paired serum & ascites fluid samples from ascitic patients were collected and analyzed. The utility of the serum - ascites albumin gradient & the exudate transudate concept as defined by ascitic fluid
Mostafa Ansari, Mehrdad Hajiloie
doaj +2 more sources
Role of insulin-like growth factor binding protein-3 in 1, 25-dihydroxyvitamin-d 3 -induced breast cancer cell apoptosis. [PDF]
, 2013 Insulin-like growth factor I (IGF-I) is implicated in breast cancer development and 1, 25-dihydroxyvitamin D3 (1, 25-D3) has been shown to attenuate prosurvival effects of IGF-I on breast cancer cells.
Brosseau, C, Colston, KW, Pirianov, G
core +2 more sources
Molecular Oncology, EarlyView.Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova +25 more
wiley +1 more source
Standards for Total Serum Protein Assays— A Collaborative Study
Clinical Chemistry, 1975 Abstract We have studied the standardization of total serum protein assay with the biuret reaction. Standard solutions were prepared from lyophilized preparations of human serum albumin and bovine serum albumin, with corrections made for volatile material and ash contents.
openaire +2 more sources
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source